TOP2A and non-small cell lung carcinoma: However, further study is needed to determine whether an anti-topoisomerase-based adjuvant chemotherapy such as etoposide can really bring more benefits to postoperative NSCLC patients with high TopIIα expression than other chemotherapy regimens.